A single center experience of sorafenib in advanced hepatocellular carcinoma patients: Evaluation of prognostic factors

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 12, 2011, Pages 1233-1238

  Song, Tianqiang ^a   Zhang, Wei ^a   Wu, Qiang ^a   Kong, Dalu ^a   Ma, Weiwei ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

adverse effects; ascites; metastasis; sorafenib

Indexed keywords

SORAFENIB;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ASCITES; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; DIARRHEA; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LYMPH NODE; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE II AS TOPIC; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PYRIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80955142670     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834bd2d0     Document Type: Article

References (17)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576. (Pubitemid 46890874)
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
5. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130:187-196.
6. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14:70-76.
7. Shim JH, Park JW, Choi JI, Park BJ, Kim CM. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009; 135: 617-625.
8. Worns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43:489-495.
9. Xu L, Li P, Lin XJ, Yuan YF, Zhang YQ, Chen MS. Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2009; 31:58-61.
10. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115:428-436.
11. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430. (Pubitemid 32844200)
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
13. Balsom SM, Li X, Trolli E, Rose J, Bloomston M, Patel T, et al. A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. Oncology 2010; 78 (3-4):210-212.
14. Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010; 22:1106-1110.
15. Welker MW, Lubomierski N, Gog C, Herrmann E, Engels K, Vogl TJ, et al. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother 2010; 22:205-211.
16. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:4293-4300. (Pubitemid 46630787)
17. Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010; 22:391-398.